Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2022 Sep;82(13):1403-1410. doi: 10.1007/s40265-022-01763-7. Epub 2022 Aug 26.
Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere; SCS triamcinolone acetonide) is a corticosteroid approved in the USA for the treatment of macular edema associated with uveitis. Suprachoroidal injection of SCS triamcinolone acetonide results in preferential distribution into the posterior segment, which may reduce the risk of corticosteroid-related adverse events, such as cataracts and intraocular pressure (IOP) elevation. In a multicenter phase III trial in patients with non-infectious uveitic macular edema, SCS triamcinolone acetonide significantly and rapidly improved visual acuity and reduced signs of macular edema compared with sham treatment. SCS triamcinolone acetonide was generally well tolerated, with the most common adverse event being eye pain on the day of the procedure. The risk of corticosteroid-related IOP elevation appeared to be reduced in unrescued patients in the SCS triamcinolone acetonide group compared with patients in the sham control group who received rescue therapy. SCS triamcinolone acetonide is a novel and useful treatment option for uveitic macular edema.
用于脉络膜上腔注射的曲安奈德混悬注射液（Xipere；SCS 曲安奈德）是一种皮质类固醇药物，在美国被批准用于治疗与葡萄膜炎相关的黄斑水肿。脉络膜上腔注射 SCS 曲安奈德可使药物优先分布到后节，这可能降低与皮质类固醇相关的不良反应（如白内障和眼压升高）的风险。在一项针对非感染性葡萄膜炎性黄斑水肿患者的多中心 III 期试验中，与假治疗相比，SCS 曲安奈德可显著且迅速改善视力，并减轻黄斑水肿的体征。SCS 曲安奈德通常具有良好的耐受性，最常见的不良反应是治疗当天的眼部疼痛。与接受挽救治疗的假对照治疗组相比，SCS 曲安奈德组中未接受挽救治疗的患者的皮质类固醇相关眼压升高风险似乎降低。SCS 曲安奈德是葡萄膜炎性黄斑水肿的一种新颖且有用的治疗选择。
